Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

9.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 444
Open 9.500
Bid (Size) 3.800 (2)
Ask (Size) 11.95 (1)
Prev. Close 9.500
Today's Range 9.500 - 9.500
52wk Range 9.020 - 14.57
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
Via Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
Via Benzinga

Performance

YTD
-33.29%
-33.29%
1 Month
-19.97%
-19.97%
3 Month
-18.80%
-18.80%
6 Month
+0.32%
+0.32%
1 Year
-10.71%
-10.71%

More News

Read More
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
From Amicus Therapeutics, Inc.
Via GlobeNewswire
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.